Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares. 
Via InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
 
Via Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT. 
Via InvestorPlace
Karuna Surges To Three-Month High On Another Win In Schizophrenia
The company is soon planning to ask for FDA approval of KarXT. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
 
Via Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
 
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
 
Via Benzinga
Analyst Expectations for Karuna Therapeutics's Future
 
Via Benzinga
Ciena, Apple And 3 Stocks To Watch Heading Into Monday
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday
Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market... 
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
5 Analysts Have This to Say About Karuna Therapeutics
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
 
Via Benzinga
Where Karuna Therapeutics Stands With Analysts
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Expert Ratings for Karuna Therapeutics
 
Via Benzinga
Why Karuna Therapeutics Shares Are Trading Sharply Lower
Karuna Therapeutics Inc (NASDAQ: KRTX) shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition. What Happened? 
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
 
Via Benzinga
My 3 Top Biotech Stock Picks for 2023
Biotech stocks are set to shine in 2023. 
Via The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Karuna Therapeutics: Q3 Earnings Insights
Karuna Therapeutics (NASDAQ:KRTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
What 12 Analyst Ratings Have To Say About Karuna Therapeutics
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
12 Analysts Have This to Say About Karuna Therapeutics
Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns. 
Via The Motley Fool
Opportunities In Large Cap Growth And Small Cap
The third quarter was true 
Via Talk Markets
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Where Karuna Therapeutics Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
7 Momentum Stocks to Buy Now for Extraordinary Gains
Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.